{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:47:51Z","timestamp":1791899271022,"version":"4.3.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"DOI":"10.1186\/s13256-026-06378-0","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T10:25:17Z","timestamp":1784283917000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Osimertinib-induced acute decompensated heart failure: a case report and review of the literature"],"prefix":"10.1186","volume":"20","author":[{"given":"Hou-Chen","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Heng","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horng-Chyuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"1","key":"6378_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1913662.","journal-title":"N Engl J Med"},{"issue":"4","key":"6378_CR2","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1200\/JCO.20.01171","volume":"39","author":"MS Ewer","year":"2021","unstructured":"Ewer MS, Tekumalla SH, Walding A, Atuah KN. Cardiac safety of osimertinib: a review of data. J Clin Oncol. 2021;39(4):328\u201337. https:\/\/doi.org\/10.1200\/JCO.20.01171.","journal-title":"J Clin Oncol"},{"issue":"16","key":"6378_CR3","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.2169\/internalmedicine.8344-16","volume":"56","author":"H Watanabe","year":"2017","unstructured":"Watanabe H, Ichihara E, Kano H, Ninomiya K, Tanimoto M, Kiura K. Congestive heart failure during osimertinib treatment for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Intern Med. 2017;56(16):2195\u20137. https:\/\/doi.org\/10.2169\/internalmedicine.8344-16.","journal-title":"Intern Med"},{"issue":"1","key":"6378_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2020.02.003","volume":"2","author":"K Kunimasa","year":"2020","unstructured":"Kunimasa K, Kamada R, Oka T, et al. Cardiac adverse events in EGFR-mutated non-small cell lung cancer treated with osimertinib. JACC CardioOncol. 2020;2(1):1\u201310. https:\/\/doi.org\/10.1016\/j.jaccao.2020.02.003.","journal-title":"JACC CardioOncol"},{"key":"6378_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2019.10.006","author":"K Anand","year":"2019","unstructured":"Anand K, Ensor J, Trachtenberg B, Bernicker EH. Osimertinib-induced cardiotoxicity: a retrospective review of the FDA adverse events reporting system (FAERS). JACC CardioOncol. 2019. https:\/\/doi.org\/10.1016\/j.jaccao.2019.10.006.","journal-title":"JACC CardioOncol."},{"issue":"1","key":"6378_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jaccao.2020.01.003","volume":"2","author":"AJ Piper-Vallillo","year":"2020","unstructured":"Piper-Vallillo AJ, Costa DB, Sabe MA, Asnani A. Heart failure associated with the epidermal growth factor receptor inhibitor osimertinib. JACC CardioOncol. 2020;2(1):119\u201322. https:\/\/doi.org\/10.1016\/j.jaccao.2020.01.003.","journal-title":"JACC CardioOncol"},{"issue":"11","key":"6378_CR7","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1158\/1078-0432.CCR-17-1875","volume":"24","author":"S Liu","year":"2018","unstructured":"Liu S, Li S, Hai J, et al. Targeting HER2 aberrations in non-small cell lung cancer with osimertinib. Clin Cancer Res. 2018;24(11):2594\u2013604. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1875.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"6378_CR8","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/j.jtho.2017.05.016","volume":"12","author":"T Oyakawa","year":"2017","unstructured":"Oyakawa T, Nakashima K, Naito T. Cardiac dysfunction caused by osimertinib. J Thorac Oncol. 2017;12(10):e159\u201360. https:\/\/doi.org\/10.1016\/j.jtho.2017.05.016.","journal-title":"J Thorac Oncol"},{"key":"6378_CR9","first-page":"52","volume":"6","author":"ML Reale","year":"2018","unstructured":"Reale ML, Bianco M, Tabb\u00f2 F, et al. Osimertinib-induced cardiac dysfunction in EGFR- mutated lung cancer: a case series of five patients. Am J Cancer Case Rep. 2018;6:52\u201360.","journal-title":"Am J Cancer Case Rep"},{"issue":"4","key":"6378_CR10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.jaccas.2019.12.038","volume":"2","author":"SR Patel","year":"2020","unstructured":"Patel SR, Brown SN, Kubusek JE, Mansfield AS, Duma N. Osimertinib-induced cardiomyopathy. JACC Case Rep. 2020;2(4):641\u20135. https:\/\/doi.org\/10.1016\/j.jaccas.2019.12.038.","journal-title":"JACC Case Rep."},{"issue":"39","key":"6378_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022301","volume":"99","author":"S Shinomiya","year":"2020","unstructured":"Shinomiya S, Kaira K, Yamaguchi O, Ishikawa K, Kagamu H. Osimertinib induced cardiomyopathy: a case report. Med (Baltimore). 2020;99(39): e22301. https:\/\/doi.org\/10.1097\/MD.0000000000022301.","journal-title":"Med (Baltimore)"},{"issue":"2","key":"6378_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58020312","volume":"58","author":"A Fukuo","year":"2022","unstructured":"Fukuo A, Imamura T, Onoda H, Kinugawa K. Successful management of osimertinib-induced heart failure. Medicina (Kaunas). 2022;58(2): 312. https:\/\/doi.org\/10.3390\/medicina58020312.","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"6378_CR13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s13691-020-00450-2","volume":"10","author":"S Ikebe","year":"2020","unstructured":"Ikebe S, Amiya R, Minami S, Ihara S, Higuchi Y, Komuta K. Osimertinib-induced cardiac failure with QT prolongation and torsade de pointes in a patient with advanced pulmonary adenocarcinoma. Int Cancer Conf J. 2020;10(1):68\u201371. https:\/\/doi.org\/10.1007\/s13691-020-00450-2.","journal-title":"Int Cancer Conf J"},{"issue":"3","key":"6378_CR14","doi-asserted-by":"publisher","first-page":"284","DOI":"10.26502\/fccm.92920263","volume":"6","author":"LC Medepalli","year":"2022","unstructured":"Medepalli LC, Jolly PC, Vallakati A, Medepalli AM. Osimertinib-cardiac dysfunction with prolonged QTc interval: a case report. Cardiol Cardiovasc Med. 2022;6(3):284\u201391.","journal-title":"Cardiol Cardiovasc Med."},{"issue":"1","key":"6378_CR15","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1159\/000533826","volume":"16","author":"Z Saito","year":"2023","unstructured":"Saito Z, Imakita T, Ito T, et al. Successful rechallenge with osimertinib following osimertinib-induced ventricular tachycardia: a case report. Case Rep Oncol. 2023;16(1):1100\u20136. https:\/\/doi.org\/10.1159\/000533826.","journal-title":"Case Rep Oncol"},{"issue":"1","key":"6378_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40959-023-00190-1","volume":"9","author":"K Patel","year":"2023","unstructured":"Patel K, Hsu KY, Lou K, et al. Osimertinib-induced biventricular cardiomyopathy with abnormal cardiac MRI findings: a case report published correction appears in cardiooncology. Cardiooncology. 2023;9(1):38. https:\/\/doi.org\/10.1186\/s40959-023-00190-1.","journal-title":"Cardiooncology."},{"issue":"2","key":"6378_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jtho.2024.10.003","volume":"20","author":"M Bak","year":"2025","unstructured":"Bak M, Park H, Lee SH, et al. The risk and reversibility of osimertinib-related cardiotoxicity in a real-world population. J Thorac Oncol. 2025;20(2):167\u201376. https:\/\/doi.org\/10.1016\/j.jtho.2024.10.003.","journal-title":"J Thorac Oncol"},{"key":"6378_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1485033","volume":"11","author":"JN Le","year":"2024","unstructured":"Le JN, Gasho JO, Peony O, et al. Cardiac events and dynamic echocardiographic and electrocardiogram changes following osimertinib treatment in lung cancer. Front Cardiovasc Med. 2024;11: 1485033. https:\/\/doi.org\/10.3389\/fcvm.2024.1485033.","journal-title":"Front Cardiovasc Med"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-026-06378-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06378-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06378-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:02:18Z","timestamp":1791896538000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13256-026-06378-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6378"],"URL":"https:\/\/doi.org\/10.1186\/s13256-026-06378-0","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"16 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was not required for this single case report, in accordance with the institutional policy.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-chief of this journal.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"618"}}